Percentages of Subjects With Human Serum Bactericidal Titer = 1:4 Against N.Meningitidis Serogroup C;Percentages of Subjects With Human Serum Bactericidal Titer = 1:8 and Titer = 1:4 Against N. Meningitidis Serogroups A, C, W, Y;Percentages of Subjects With Human Serum Bactericidal Titer = 1:8 and Titer = 1:4 Against N. Meningitidis Serogroups A, W, Y;Human Serum Bactericidal Activity Geometric Mean Titers After One Dose of MenACWY-CRM197 and MenC Against N.Meningitidis Serogroup C;Human Serum Bactericidal Activity Geometric Mean Titers Against N.Meningitidis Serogroups A, W, Y;Human Serum Bactericidal Activity Geometric Mean Titers Against N.Meningitidis Serogroups A, C, W, Y;Percentages of Subjects With Seroresponse Rates After One Dose of DTPa-IPV-HepB-Hib (Concomitant Vaccine);Percentages of Subjects With Seroresponse Rates After One Dose of PCV7 (Concomitant Vaccine);Persistence of Immune Response Measured as Percentages of Subjects With Human Serum Bactericidal Titer = 1:8 and Titer = 1:4 Against N. Meningitidis Serogroup C;Persistence of Immune Response Measured as Percentages of Subjects With Human Serum Bactericidal Titer = 1:8 ,and Titer = 1:4 Against N. Meningitidis Serogroups A, W, Y;Persistence of Human Serum Bactericidal Activity Geometric Mean Titers Against N.Meningitidis Serogroup C;Persistence of Human Serum Bactericidal Activity Geometric Mean Titers Against N.Meningitidis Serogroups A, W, Y;Percentages of Subjects With Rabbit Serum Bactericidal = 1:8, = 1:128 and Four Fold Rise Against N.Meningitidis Serogroup C;Percentages of Subjects With Rabbit Serum Bactericidal = 1:8, = 1:128, and Four Fold Rise Against N.Meningitidis Serogroup A, W, Y;Rabbit Serum Bactericidal Activity Geometric Mean Titers Against N.Meningitidis Serogroup C;Rabbit Serum Bactericidal Activity Geometric Mean Titers Against N.Meningitidis Serogroup A, W, Y;Number of Subjects Who Reported Solicited Local and Systemic Reactions (Day 1 to Day 7 Postvaccination), After Any Vaccination